PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial

Ann Hematol. 2004:83 Suppl 1:S89-90. doi: 10.1007/s00277-004-0850-2.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Blast Crisis
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / pathology
  • Protein Kinase C / antagonists & inhibitors*
  • Proto-Oncogene Proteins / antagonists & inhibitors
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
  • fms-Like Tyrosine Kinase 3

Substances

  • Enzyme Inhibitors
  • Proto-Oncogene Proteins
  • FLT3 protein, human
  • Receptor Protein-Tyrosine Kinases
  • fms-Like Tyrosine Kinase 3
  • Protein Kinase C